Sensus Healthcare, Inc. Expected to Post Q4 2024 Earnings of $0.15 Per Share (NASDAQ:SRTS)

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Equities researchers at HC Wainwright increased their Q4 2024 EPS estimates for Sensus Healthcare in a report issued on Monday, May 13th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $0.15 per share for the quarter, up from their prior estimate of $0.14. HC Wainwright currently has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Sensus Healthcare's Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.22 EPS and FY2025 earnings at $0.47 EPS.

Separately, Maxim Group lifted their target price on shares of Sensus Healthcare from $7.00 to $10.00 and gave the company a "buy" rating in a research note on Friday.

Sensus Healthcare Price Performance

NASDAQ:SRTS traded down $0.10 during trading hours on Tuesday, hitting $5.30. The company had a trading volume of 683,557 shares, compared to its average volume of 392,478. The stock has a 50-day moving average price of $3.71 and a 200 day moving average price of $3.20. The company has a market capitalization of $86.89 million, a PE ratio of 18.28 and a beta of 0.92. Sensus Healthcare has a 52 week low of $1.79 and a 52 week high of $5.85.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.18. Sensus Healthcare had a return on equity of 10.01% and a net margin of 14.70%. The business had revenue of $10.66 million during the quarter, compared to analyst estimates of $4.33 million. During the same quarter in the prior year, the company posted ($0.12) EPS.

Institutional Investors Weigh In On Sensus Healthcare

Several hedge funds have recently made changes to their positions in SRTS. Creekmur Asset Management LLC bought a new position in Sensus Healthcare in the fourth quarter worth $83,000. Hillsdale Investment Management Inc. bought a new position in shares of Sensus Healthcare in the 1st quarter worth about $155,000. Sachetta LLC purchased a new position in Sensus Healthcare during the 4th quarter valued at about $247,000. Finally, Perritt Capital Management Inc. boosted its stake in Sensus Healthcare by 5.0% during the third quarter. Perritt Capital Management Inc. now owns 105,586 shares of the company's stock worth $292,000 after acquiring an additional 5,000 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.